Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients

Journal of Hepatology

Volumn 50, Issue 4, 2009, Pages 712-718

  Dai, Chia Yen ^a,b,c   Huang, Jee Fu ^a,d   Hsieh, Ming Yen ^a   Hou, Nai Jen ^a,d   Lin, Zu Yau ^a,b   Chen, Shinn Chern ^a,b   Hsieh, Ming Yuh ^a,b   Wang, Liang Yen ^a,b   Chang, Wen Yu ^a,b   Chuang, Wan Long ^a,b   Yu, Ming Lung ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

Chronic hepatitis C; Combination therapy; Genotype; Insulin resistance; The homeostasis assessment model

Indexed keywords

INSULIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CELL FUNCTION; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PANCREAS ISLET CELL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 61849108171     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.12.017     Document Type: Article

References (41)

1. Mazzaro C., Panarello G., Tesio F., Santini G., Crovatto M., Mazzi G., et al. Hepatitis C virus risk: a hepatitis C virus-related syndrome. J Intern Med 247 (2000) 535-545
2. Hadziyannis S.J. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat 4 (1997) 9-28
3. Huang J.F., Chuang W.L., Dai C.Y., Ho C.K., Hwang S.J., Chen S.C., et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: Another chain of link?. J Intern Med 260 (2006) 255-262
4. Simo R., Hernandez C., Genesca J., Jardi R., and Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19 (1996) 998-1000
5. Mason A.L., Lau J.Y., Hoang N., Qian K., Alexander G.J., Xu L., et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29 (1999) 328-333
6. Knobler H., Schihmanter R., Zifroni A., Fenakel G., and Schattner A. Increased risk of type 2 diabetes in non-cirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 75 (2000) 355-359
7. Dai C.Y., Chuang W.L., Ho C.K., Hsieh M.Y., Huang J.F., Lee L.P., et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 49 (2008) 9-16
8. Petrides A.S. Liver disease and diabetes mellitus. Diabetes Rev 2 (1994) 2-18
9. Petit J.M., Bour J.B., Galland-Jos C., Minello A., Verges B., Guiguet M., et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 35 (2001) 279-283
10. Hui J.M., Sud A., Farrell G.C., Bandara P., Byth K., Kench J.G., et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125 (2003) 1695-1704
11. Taura N., Ichikawa T., Hamasaki K., Nakao K., Nishimura D., Goto T., et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 101 (2006) 2752-2759
12. Svegliati-Baroni G., Bugianesi E., Bouserhal T., Marini F., Ridolfi F., Tarsetti F., et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in nonalcoholic fatty liver disease. Gut 56 (2007) 1296-1301
13. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
14. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
15. Sterling R.K., Hofmann C.M., Luketic V.A., Sanyal A.J., Contos M.J., Mills A.S., et al. Treatment of chronic hepatitis C virus in the Virginia department of corrections: Can compliance overcome racial differences to response?. Am J Gastroenterol 99 (2004) 866-872
16. Bressler B.L., Guindi M., Tomlinson G., and Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38 (2003) 639-644
17. Muir A.J., Bornstein J.D., and Killenberg P.G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350 (2004) 2265-2271
18. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
19. Lee S.D., Yu M.L., Cheng P.N., Lai M.Y., Chao Y.C., Hwang S.J., et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 12 (2005) 283-291
20. Yu M.L., Dai C.Y., Huang J.F., Hou N.J., Lee L.P., Hsieh M.Y., et al. A randomized study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56 (2007) 553-559
21. Yu M.L., Dai C.Y., Huang J.F., Chiu C.F., Yang Y.H., Hou N.J., et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology 47 (2008) 1884-1893
22. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., Salmeron J., Diago M., Fernandez-Rodriguez C.M., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128 (2005) 636-641
23. Poustchi H., Negro F., Hui J., Cua I.H., Brandt L.R., Kench J.G., et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 48 (2008) 28-34
24. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1982) 431-435
25. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13 (1991) 372-374
26. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
27. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28 (1985) 412-429
28. Okamoto H., Tokita H., Sakamoto M., Horikita M., Kojima M., Iizuka H., et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 74 (1993) 2385-2390
29. Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party. McCaughan G.W., Omata M., Amarapurkar D., et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 22 (2007) 615-633
30. Dai C.Y., Chuang W.L., Chang W.Y., Chen S.C., Lee L.P., Hsieh M.Y., et al. Tumor necrosis factor alpha promoter polymorphism at position -308 predicts hepatitis C virus response to combination therapy. J Infect Dis 193 (2006) 98-101
31. Labropoulou-Karatza C., Goritsas C., Fragopanagou H., Repandi M., Matsouka P., and Alexandrides T. High prevalence of diabetes mellitus among adult β-thalassemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 11 (1999) 1033-1036
32. Huang J.F., Dai C.Y., Hwang S.J., Ho C.K., Hsiao P.J., Hsieh M.Y., et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol 102 (2007) 1237-1243
33. Mangia A., Santoro R., Minerva N., Ricci G.L., Carretta V., Persico M., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352 (2005) 2609-2617
34. Conjeevaram H.S., Kleiner D.E., Everhart J.E., Hoofnagle J.H., Zacks S., Afdhal N.H., et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45 (2007) 80-87
35. Powell E.E., Jonsson J.R., and Clouston A.D. Steatosis: co-factor in other liver diseases. Hepatology 42 (2005) 5-13
36. Hsieh M.H., Lee L.P., Hsieh M.Y., Tsai K.B., Huang J.F., Hou N.J., et al. Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan. Jpn J Infect Dis 60 (2007) 377-381
37. D'Souza R., Sabin C.A., and Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100 (2005) 1509-1515
38. Muzzi A., Leandro G., Rubbia-Brandt L., James R., Keiser O., Malinverni R., et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 42 (2005) 41-46
39. Sud A., Hui J.M., Farrell G.C., Bandara P., Kench J.G., Fung C., et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 39 (2004) 1239-1247
40. Zekry A., McHutchison J.G., and Diehl A.M. Insulin resistance and steatosis in hepatitis C virus infection. Gut 54 (2005) 903-906
41. Fartoux L., Poujol-Robert A., Gue'chot J., Wendum D., Poupon R., and Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54 (2005) 1003-1008